about
Structural features impose tight peptide binding specificity in the nonclassical MHC molecule HLA-ERequirement of the proteasome for the trimming of signal peptide-derived epitopes presented by the nonclassical major histocompatibility complex class I molecule HLA-EHuman congenital infection with Trypanosoma cruzi induces phenotypic and functional modifications of cord blood NK cellsThe human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9HLA-E binds to natural killer cell receptors CD94/NKG2A, B and CCutting edge: lectin-like transcript 1 is a ligand for the CD161 receptorThe T cell surface--how well do we know it?Lack of binding of peptides carrying the human platelet antigen 1 (HPA-1) dimorphism to purified HLA-DRw52a molecules.Susceptibility to alloimmunization to platelet HPA-1a antigen involves TAP1 polymorphism.Functions of nonclassical MHC and non-MHC-encoded class I molecules.Expression of a single-chain HLA class I molecule in a human cell line: presentation of exogenous peptide and processed antigen to cytotoxic T lymphocytesUL40-mediated NK evasion during productive infection with human cytomegalovirus.Human cytomegalovirus UL40 signal peptide regulates cell surface expression of the NK cell ligands HLA-E and gpUL18NKp46+ Innate Lymphoid Cells Dampen Vaginal CD8 T Cell Responses following Local Immunization with a Cholera Toxin-Based Vaccine.Lectin-like transcript 1 is a marker of germinal center-derived B-cell non-Hodgkin's lymphomas dampening natural killer cell functionsNatural killer cell behavior in lymph nodes revealed by static and real-time imaging.Magnitude of alloresponses to MHC class I/II expressing human cardiac myocytes is limited by their intrinsic ability to process and present antigenic peptides.Silencing of the tandem pore domain halothane-inhibited K+ channel 2 (THIK2) relies on combined intracellular retention and low intrinsic activity at the plasma membrane.Sublingual Priming with a HIV gp41-Based Subunit Vaccine Elicits Mucosal Antibodies and Persistent B Memory Responses in Non-Human Primates.Natural killer cell responses to infections in early life.Mechanisms of NK cell activation: CD4(+) T cells enter the scene.B cell and T cell immunity in the female genital tract: potential of distinct mucosal routes of vaccination and role of tissue-associated dendritic cells and natural killer cells.A real-time digital bio-imaging system to quantify cellular cytotoxicity as an alternative to the standard chromium-51 release assay.Killer cell immunoglobulin-like receptor expression induction on neonatal CD8(+) T cells in vitro and following congenital infection with Trypanosoma cruzi.Recognition of HLA-A3 and HLA-A11 by KIR3DL2 is peptide-specific.A Real-Time Cytotoxicity Assay as an Alternative to the Standard Chromium-51 Release Assay for Measurement of Human NK and T Cell Cytotoxic Activity.Expression of CD94-NKG2A inhibitory receptor is restricted to a subset of CD8+ T cells.The proteasome-specific inhibitor lactacystin blocks presentation of cytotoxic T lymphocyte epitopes in human and murine cellsEffects of MHC-encoded TAP1 and TAP2 gene polymorphism and matching on kidney graft rejectionMembranous nephropathy and a TAP1 gene polymorphismCell-surface expression and immune receptor recognition of HLA-B27 homodimersSignificance of serum bile acids in small bowel allograft rejection in pigsPrimed antigen-specific CD4+ T cells are required for NK cell activation in vivo upon Leishmania major infectionAntigen-bearing dendritic cells from the sublingual mucosa recirculate to distant systemic lymphoid organs to prime mucosal CD8 T cellsExpression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcomeNK Cell and Fibroblast-Mediated Regulation of Skin Squamous Cell Carcinoma Invasion by CLEC2A Is Compromised in Xeroderma PigmentosumA size and space structured model describing interactions of tumor cells with immune cells reveals cancer persistent equilibrium states in tumorigenesis
P50
Q27760580-DE76EFCC-AA44-4F60-B5E3-DAA629A6E0E6Q28181479-63B07F29-62EA-4167-8C38-A8132B93956BQ28239745-341C1B4C-904C-4D87-957D-7A3B0C61ED5CQ28239867-254F2917-99F5-4A5B-88D8-F12F3A7300FCQ28263511-DE388791-9FC0-4EB2-8F7D-9E2E6B6010BAQ28286015-0BC9C677-CE63-47DA-807F-7E908BA089FAQ30977864-BDF36633-A8A1-4377-84E1-C06D4E8333BBQ33487781-EACD0A9D-0B59-4F12-B05A-F86E69CF4B16Q33490483-833B7BB2-0BEC-4D0D-8524-9E83421B1E13Q33536532-A5B4B232-0F3F-45E1-AAF8-3E51698CD27BQ33612515-0B20138A-EE6B-4D85-B289-D8E1F7C510ACQ34064598-1F12A568-AD76-46DD-893E-3A208C95F1F2Q35828380-B962EA78-3B38-4BBF-A695-DD19F31FF5F9Q35858827-E37A7351-DF83-4C5A-85FB-8BB6EDBCF0F0Q36060329-309069CD-8EA5-428A-A7DE-57E741CBF8F9Q36228348-D2246CF1-F38D-4193-9324-22B788988199Q36792996-AD4139AA-C478-4583-87B4-4E3756A75A53Q37368625-3C4514B3-DF73-45BA-9DE7-CCC8B1D2C85AQ37617455-903255A1-5143-4D3A-8876-165FB0DF531BQ37853786-2C85C0FD-8446-4FF7-BC04-F7ECF4EE83D9Q37921196-8ADEA945-FF10-48C2-8CA4-84E47BAF3A2FQ38033664-F23E392B-1E55-4A48-A5B8-0E9E397D58DAQ40430440-6A0930E6-7FA3-4DEB-AB08-C1B9858AB4BFQ43239562-3BCA0EE5-2492-494A-9072-C8D8C3C55778Q47431117-BDC3CC13-BC54-4D93-ADB6-F747E10B8FC8Q50515089-4D30FDEB-B6BD-40CE-B718-D0F32A7EF364Q51026945-92B8F7D9-CF37-4A6E-A60C-B1933C4919F9Q59167181-9A09416B-E2E3-46F6-9922-F0C2782BC9AFQ71983580-B794B3F1-5A46-4378-BE12-0738EE62221FQ72529441-A6BB0136-5E32-44F7-A307-0F936B6A3FCDQ78505485-A6601FAD-F92B-4101-8FEF-D093B9ABA232Q83173289-5678C109-43D3-4B0B-A201-8C11C6065215Q84563084-97749DE2-B345-485E-A6D5-DAD4D4112250Q87003088-10D25BEB-E1DB-488D-A18F-AF89525127C4Q88550353-C93BDC9C-B525-47B9-92C2-084A93A4AE0FQ89728357-74302D55-79D6-4647-B2B7-65AA7735AFB1Q92937876-77DCB5B4-6F46-40DE-97B6-D518C606A139
P50
description
researcher
@en
wetenschapper
@nl
name
V Braud
@en
V Braud
@nl
type
label
V Braud
@en
V Braud
@nl
prefLabel
V Braud
@en
V Braud
@nl
P106
P31
P496
0000-0001-8213-3947